TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06454188: A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

Sponsor: CARE ARTHRITIS LTD. · Phase: PHASE4 · Area: IMMUNOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$3,229,200

Rescue Site Savings

+$2,125,200

Unlock Full NCT06454188 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06454188 Rescue Dossier →